Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco, Oct. 1–3. SynBioBeta is a prominent network of biological engineers, investors, innovators and entrepreneurs.

“The optionality to design a new protein molecule is effectively infinite,” said Codexis CEO John Nicols, a featured speaker at the conference. “Our CodeEvolver^® protein engineering platform technology melds artificial intelligence, machine learning and synthetic biology toolkits to continuously accelerate the identification of new value creating protein based products, targeting a wide range of industries and applications. We are excited to showcase CodeEvolver^® and our growing list of real-world commercial success stories at this premier synthetic biology innovation networking event next week.” CodeEvolver^® is the company’s proprietary protein engineering platform.

Codexis, a gold sponsor of the summit, is either featured in or hosting the following events:

• Successful Partnering in the Bioeconomy
  Fireside Chat
  October 2, 10:10-10:40 a.m.
  Nicols and Tate & Lyle CTO Michael Harrison will discuss their companies’ partnership and how vital successful partnering is to the industry.
• Commercial Success of CodeEvolver^®
  Workshop
  October 2, 12:30–1:15 p.m.
  Dipnath Baidyaroy, Ph.D., senior director of strategic alliances and business operations and Jonathan Vroom, Ph.D., principal scientist, explain how Codexis has used its unique CodeEvolver^® protein engineering technology to rapidly gain success in commercial markets.
• Wide Applications of Protein Engineering
  Breakout Session
  October 3, 2:30–3:15 p.m.
  • Gjalt Huisman, Ph.D., senior vice president of strategic development, will moderate.
  • Matt Miller, Ph.D., senior scientist, will present: RNA polymerase for capped messenger RNA manufacturing & DNA polymerase for next-gen sequencing.
  • Kerryn McCluskie, Ph.D., senior director of translational biology, will present: Orally administrable biotherapeutics.
  • Oscar Alvizo, Ph.D., director of computational biology, will present: AI/machine learning in protein engineering.

Attendees are also invited to visit Codexis at booth #212.

About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver^® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2018 and Quarterly Report on Form 10-Q filed November 9, 2018, including under the caption “Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005186/en/